Elise Siegert1, Christine March1, Lindsey Otten2, Alexander Makowka1, Emelina Preis1, Frank Buttgereit1, Gabriela Riemekasten3, Ursula Müller-Werdan2, Kristina Norman4. 1. Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; Department of Rheumatology and Clinical Immunology, Berlin, Germany. 2. Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; Research Group on Geriatrics, Working Group Nutrition and Body Composition, Berlin, Germany. 3. Department of Rheumatology, University of Lubeck, Lubeck, Germany; Research Center Borstel, Airway Research Center North, Members of the German Center for Lung Research, Grosshansdorf, Germany. 4. Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; Research Group on Geriatrics, Working Group Nutrition and Body Composition, Berlin, Germany; Department of Nutrition and Gerontology, German Institute of Human Nutrition, Potsdam-Rehbrücke, Germany. Electronic address: kristina.norman@charite.de.
Abstract
OBJECTIVE: We analyzed the prevalence of sarcopenia among systemic sclerosis (SSc) patients with respect to quality of life, disability, organ involvement, and muscle function. METHODS: A total of 129 patients who met the ACR/EULAR 2013 classification criteria were included. Body composition was measured using bioelectric impedance analysis. Sarcopenia was defined according to the criteria of the European Working Group on Sarcopenia in Older People. Handgrip and knee extension strength and pulmonary peak flow were measured. Physical function was assessed with the Short Form-36 Health Survey and Scleroderma Health Assessment Questionnaire. RESULTS: Sarcopenia was prevalent in 22.5% of patients. There were significant differences between patients with and without sarcopenia regarding handgrip strength (11.5 [2.0-30.0] versus 18.0 [1.0-41.0] kilogram force [kgf]; P <0.001) and knee extension strength (11.0 [3.5-32.5] versus 17.5 [3.5-88.0] kgf; P = 0.006), physical function (38.8 [9.9-85.0] versus 48.8 [0-88.0]; P = 0.032) and number of immunosuppressants (2 [0-4] versus 1 [0-5]; P = 0.009). There were no differences regarding age (57.0 [32.0-83.0] versus 60.5 [28.0-82.0] years; P = 0.350) and disease duration (8 [1-27] versus 7 [0-34] years; P = 0.350). CONCLUSIONS: Sarcopenia is common in patients with SSc and is associated with physical impairment that affects everyday life and participation in work. Interestingly, although age is the main risk factor for sarcopenia in the general population, it did not differ between sarcopenic and non-sarcopenic SSc patients in our study. Instead, the number of immunosuppressive drugs was significantly higher among sarcopenic patients.
OBJECTIVE: We analyzed the prevalence of sarcopenia among systemic sclerosis (SSc) patients with respect to quality of life, disability, organ involvement, and muscle function. METHODS: A total of 129 patients who met the ACR/EULAR 2013 classification criteria were included. Body composition was measured using bioelectric impedance analysis. Sarcopenia was defined according to the criteria of the European Working Group on Sarcopenia in Older People. Handgrip and knee extension strength and pulmonary peak flow were measured. Physical function was assessed with the Short Form-36 Health Survey and Scleroderma Health Assessment Questionnaire. RESULTS:Sarcopenia was prevalent in 22.5% of patients. There were significant differences between patients with and without sarcopenia regarding handgrip strength (11.5 [2.0-30.0] versus 18.0 [1.0-41.0] kilogram force [kgf]; P <0.001) and knee extension strength (11.0 [3.5-32.5] versus 17.5 [3.5-88.0] kgf; P = 0.006), physical function (38.8 [9.9-85.0] versus 48.8 [0-88.0]; P = 0.032) and number of immunosuppressants (2 [0-4] versus 1 [0-5]; P = 0.009). There were no differences regarding age (57.0 [32.0-83.0] versus 60.5 [28.0-82.0] years; P = 0.350) and disease duration (8 [1-27] versus 7 [0-34] years; P = 0.350). CONCLUSIONS:Sarcopenia is common in patients with SSc and is associated with physical impairment that affects everyday life and participation in work. Interestingly, although age is the main risk factor for sarcopenia in the general population, it did not differ between sarcopenic and non-sarcopenic SScpatients in our study. Instead, the number of immunosuppressive drugs was significantly higher among sarcopenic patients.
Authors: V Smith; M Cutolo; S Paolino; E Gotelli; F Goegan; A Casabella; G Ferrari; M Patane; M Albertelli; F Gatto; C Pizzorni; F Cattelan; A Sulli Journal: J Endocrinol Invest Date: 2020-05-24 Impact factor: 4.256
Authors: Fausto Salaffi; Marina Carotti; Andrea Di Matteo; Luca Ceccarelli; Sonia Farah; Catalina Villota-Eraso; Marco Di Carlo; Andrea Giovagnoni Journal: Radiol Med Date: 2022-09-20 Impact factor: 6.313
Authors: Wilfred Manzano; Leon Lenchik; Akshay S Chaudhari; Lawrence Yao; Sarthak Gupta; Robert D Boutin Journal: Skeletal Radiol Date: 2021-07-16 Impact factor: 2.199
Authors: Hyo Jin An; Kalthoum Tizaoui; Salvatore Terrazzino; Sarah Cargnin; Keum Hwa Lee; Seoung Wan Nam; Jae Seok Kim; Jae Won Yang; Jun Young Lee; Lee Smith; Ai Koyanagi; Louis Jacob; Han Li; Jae Il Shin; Andreas Kronbichler Journal: Int J Mol Sci Date: 2020-08-07 Impact factor: 5.923